Berkovich RR, et al. - Experts analyzed the potential efficacy and safety profile of dextromethorphan/quinidine (DMQ) in the prophylactic treatment of migraine in patients with multiple sclerosis (MS) with superimposed pseudobulbar affect (PBA) and comorbid migraine, carried out at the University of Southern California Comprehensive MS Center. During this study, the DMQ was used exclusively per its primary indication —PBA symptoms control— 20/10 mg orally, twice a day for the mean of 4.5 months. Among the 33 MS subjects with PBA, who also suffered from migraines, a total of 29 enrollees exhibited improvement in headache frequency. An improvement in headache severity was illustrated among 28 patients. Worsening of symptoms was not reported in any patients. Therefore, it was deduced that DMQ was useful in the prevention of migraine headaches in the study cohort.